RESUMO
A population-based study was undertaken to determine the short term risk of death in English patients diagnosed with meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia. All patients with an MRSA-positive blood culture taken in 2004 and 2005 in England identified through routine surveillance were matched to the national registry of deaths. The study found an overall case fatality (all-cause) within 7 days of MRSA-positive blood culture diagnosis of 20%, rising to 38% within 30 days. Risk of death was highest on the day subsequent to the blood specimen being drawn (4%). Seven-day case fatality rates in women were 16% higher than for men (odds ratio: 1.16; 95% confidence interval: 1.04-1.29), although no significant difference was discernable by day 30. Risk of death increased with rising age, with 28% (425/1513) of patients aged ≥85 years dying within 7 days and 57% (859/1513) within 30 days. A seasonal pattern in case fatality rates was evident, highest in the winter and lowest in the summer. The age-standardised mortality ratios within the first week were 180 and 225 times as high for men and women, respectively, as for the general population. This declined rapidly after 10 weeks to approximately 9 for both sexes. An estimated 5.53 deaths per 100,000 population followed MRSA bacteraemia in 2004 and 2005, although no inference on causality or attributable mortality could be made through this study. The stable, elevated risk of death observable after 10 weeks compared with that in the general population gave an indication of the background risk of death unrelated to MRSA infection.
Assuntos
Bacteriemia/epidemiologia , Bacteriemia/mortalidade , Staphylococcus aureus Resistente à Meticilina/isolamento & purificação , Infecções Estafilocócicas/epidemiologia , Infecções Estafilocócicas/mortalidade , Adolescente , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Bacteriemia/microbiologia , Criança , Pré-Escolar , Inglaterra/epidemiologia , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Estações do Ano , Fatores Sexuais , Infecções Estafilocócicas/microbiologia , Adulto JovemRESUMO
OBJECTIVES: Enterobacteriaceae with extended-spectrum beta-lactamases (ESBLs) are now widespread and simple phenotypic tests are required to detect them in diagnostic laboratories. We investigated the performance of screening methods at 16 hospitals in South-East England. METHODS: Sixteen laboratories in South-East England submitted 1195 consecutive Enterobacteriaceae isolates found to be resistant, by their routine methods, to any or all of cefpodoxime, ceftazidime and cefotaxime. These isolates were re-tested centrally with various cephalosporin/clavulanate combinations and with multiplex PCR for bla(CTX-M) and bla(AmpC) alleles. RESULTS: Screening methods among the laboratories were the following: cefpodoxime discs alone (1 site); cefpodoxime, cefotaxime and ceftazidime discs (9 sites) or agar dilution (1 site); Phoenix (2 sites), Vitek 1 (1 site) and Vitek 2 (2 sites). A total of 8% of isolates submitted based on disc tests proved fully cephalosporin-susceptible, compared with 3% sent based on tests with automated systems and none of those sent based on agar dilution tests. Among isolates submitted solely on cefpodoxime resistance 256/372 (69%) proved cephalosporin-susceptible or had only borderline resistance with no clear mechanism demonstrable; this proportion decreased to 28/160 (18%) for those submitted on the basis of resistance to ceftazidime, 18/122 (15%) for those resistant to cefotaxime and 26/496 (5%) for those resistant to both cefotaxime and ceftazidime. The inference of ESBL production by Vitek 2 had the best agreement with reference laboratory results. CONCLUSIONS: Many isolates found resistant only to cefpodoxime at the source sites proved not to have ESBLs or AmpC; screening with cefotaxime and ceftazidime allowed better specificity for identification of mechanism-based resistance, as did the automated systems. Cefpodoxime disc tests nevertheless remain a useful primary screen for laboratories prepared only to test one agent.
Assuntos
Cefalosporinas/farmacologia , Enterobacteriaceae/efeitos dos fármacos , Testes de Sensibilidade Microbiana/métodos , Farmacorresistência Bacteriana/genética , Enterobacteriaceae/genética , Humanos , Reação em Cadeia da Polimerase , beta-Lactamases/análise , beta-Lactamases/genéticaAssuntos
Antibacterianos/farmacologia , Enterobacteriaceae/efeitos dos fármacos , Minociclina/análogos & derivados , Resistência beta-Lactâmica , beta-Lactamases/biossíntese , DNA Bacteriano/genética , Inglaterra , Enterobacteriaceae/enzimologia , Enterobacteriaceae/isolamento & purificação , Infecções por Enterobacteriaceae/microbiologia , Humanos , Testes de Sensibilidade Microbiana , Minociclina/farmacologia , Reação em Cadeia da Polimerase , Tigeciclina , beta-Lactamases/genéticaRESUMO
OBJECTIVES: To ascertain the agreement between MICs determined at a central laboratory, and susceptible, intermediate and resistant categorizations based on zone diameters recorded at diagnostic laboratories using the BSAC standardized method. METHODS: Standardized disc susceptibility tests were performed at sentinel laboratories in three surveys, with MIC tests performed on the collected isolates at a reference laboratory. The organisms comprised over 3300 Enterobacteriaceae, Acinetobacter spp., pseudomonads, staphylococci and enterococci, with over 29 000 antibiotic/organism tests in total. RESULTS: More than 90% of the antibiotic/organism combinations classed as susceptible by disc tests in the sentinel laboratories were confirmed by MIC testing. Disagreements were more frequent where disc tests indicated resistance, with half of the piperacillin/tazobactam resistance and one-third of the cephalosporin resistance found in Enterobacteriaceae by disc tests not being confirmed, and with three-quarters of teicoplanin resistance in enterococci not confirmed. None of the few apparent cases of meropenem resistance in Enterobacteriaceae or linezolid, quinupristin/dalfopristin or vancomycin resistance in staphylococci were confirmed by MIC testing. When disagreements were found between disc- and MIC-based categorization, MICs were commonly, although not invariably, one to three doubling dilutions above or below the breakpoint. However, many of the disagreements where MICs were three or more dilutions from the breakpoint were not seen when disc tests were repeated in the central laboratory. CONCLUSIONS: The BSAC disc method seems adequate for confirming susceptibility to guide therapy and to monitor resistance trends. Nevertheless, there must be concern about the over-estimation of many resistances, and frequent zone:MIC disagreements for isolates with borderline susceptibility.
Assuntos
Bactérias/efeitos dos fármacos , Testes de Sensibilidade Microbiana/normas , Infecções Bacterianas/microbiologia , Coleta de Dados , Humanos , Laboratórios , Testes de Sensibilidade Microbiana/métodos , Padrões de Referência , Reprodutibilidade dos Testes , Reino UnidoRESUMO
Piperacillin/tazobactam is used for empirical therapy of severe and complex infections. We assessed its activity, 9 years after launch, against consecutive, clinically significant isolates from in-patients in UK and Ireland. Standardised disc susceptibility tests were performed on 5031 isolates at 28 hospitals. For quality assurance purposes, 5% of these isolates were collected centrally for MIC tests, as were those with exceptional resistances. Compared with a similar pre-launch survey in 1991, there were major increases in the proportions of Staphylococcus aureus, Pseudomonas aeruginosa, beta-haemolytic streptococci and Enterococcus faecium isolates collected, balanced by decreases in Escherichia coli, Proteus mirabilis and coagulase-negative staphylococci. These changes in species prevalence mostly favoured organisms with inherent resistance(s) or-in the case of S. aureus-reflected the massive increase of MRSA, up from 0.7% of all isolates in 1991 to 14.8% in 2001. Based on the disc tests, piperacillin/tazobactam retained activity against 87% of Enterobacteriaceae isolates, 95% of P. aeruginosa, 99% of streptococci and 96% of Enterococcus faecalis. Resistance nevertheless had increased since 1991 in E. coli from 4 to 10%, Klebsiella spp. (5 to 21%) and in AmpC-inducible Enterobacteriaceae (17 to 23%), though not in P. mirabilis or P. aeruginosa. MIC tests confirmed most of the piperacillin/tazobactam resistance found by disc tests in Enterobacter spp., but indicated susceptibility for about half of the E. coli isolates recorded as resistant in disc tests. This situation might be remedied by reducing the zone breakpoint, but this would increase the "false susceptible" rate unacceptably. Thus, if disc tests suggest that an isolate is marginally resistant to piperacillin/tazobactam and the drug is sought as therapy, it is recommended that MIC be determined with, e.g., an Etest.